|
Aug 29
|
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
|
|
Aug 28
|
Innovent Announces 2024 Interim Results and Business Updates
|
|
Aug 28
|
High Growth Tech Stocks to Watch in Hong Kong August 2024
|
|
Aug 27
|
Exploring 3 High Growth Tech Stocks in Hong Kong
|
|
Jul 26
|
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
|
|
Jun 14
|
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
|
|
Jun 13
|
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
|
|
Jun 12
|
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
|
|
May 21
|
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
|
|
May 20
|
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
|
|
Jan 9
|
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
|
|
Dec 19
|
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
|
|
Dec 18
|
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
|
|
Dec 7
|
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
|
|
Dec 6
|
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
|
|
Dec 1
|
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
|
|
Nov 30
|
Innovent's MSCI ESG Rating Upgraded to A
|
|
Nov 6
|
Health Care Roundup: Market Talk
|
|
Nov 6
|
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
|
|
Jul 3
|
Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
|